South Korea's Samsung Biologics Co., the world’s largest contract drugmaker, said on Tuesday it signed a $1.4 billion contract manufacturing organization (CMO) deal with an unidentified European biopharmaceutical firm.
This deal marked the company's largest-ever CMO contract, representing 56.15% of its 2024 revenue and 40% of orders it received last year.
The contract runs through Dec. 31, 2030. The client and product names weren't disclosed due to a confidentiality agreement.
Samsung Biologics said the latest contract surpassed the $1.1 billion CMO deal with an Asian pharmaceutical company it inked last October.
Since its foundation, the company's cumulative orders have exceeded $17.6 billion.
Samsung Biologics is building a fifth plant with an annual production capacity of 180,000 liters, which is expected to be operational in April.
After the plant comes online, it will have a total capacity of 784,000 liters per year, the company said.
Write to Jeong Min Nam at peux@hankyung.com
Samsung Biologics' plant No. 4 in Songdo, Incheon Samsung Biologics Co., the world’s largest contract drugmaker, said on Thursday it has signed an initial agreement with LigaChem Biosciences Inc., a South Korean biotech startup, to jointly develop and produce antibody-drug conjugate (ADC)
Samsung Biologics' plant No. 4 Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combined $668 million with an unidentified European biopharmaceutical firm.The contracts, in effect through the end of 203
Samsung Biologics headquarters building (Courtesy of Samsung Biologics) Samsung Biologics Co. has agreed with South Korean biotech company LegoChem Biosciences Inc. to provide contract development organization (CDO) services for the development of antibody-drug conjugate (ADC) therapies. The wo